UA62919C2 - Method (variants) and composition for treating asthma - Google Patents

Method (variants) and composition for treating asthma Download PDF

Info

Publication number: UA62919C2
Authority: UA; Ukraine
Prior art keywords: heparins; composition; fact; molecular weight; antigen
Prior art date: 1995-08-18

Application number

UA98020876A

Other languages

English (en)

Ukrainian (uk)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-18

Filing date

1996-08-13

Publication date

2004-01-15

1996-08-13 Application filed filed Critical

2004-01-15 Publication of UA62919C2 publication Critical patent/UA62919C2/uk

Links

208000006673 asthma Diseases 0.000 title claims abstract description 43
238000000034 method Methods 0.000 title claims abstract description 38
239000000203 mixture Substances 0.000 title claims description 51
239000000427 antigen Substances 0.000 claims abstract description 82
102000036639 antigens Human genes 0.000 claims abstract description 71
108091007433 antigens Proteins 0.000 claims abstract description 71
229940127215 low-molecular weight heparin Drugs 0.000 claims abstract description 15
230000037396 body weight Effects 0.000 claims abstract description 8
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
229960002897 heparin Drugs 0.000 claims description 71
229920000669 heparin Polymers 0.000 claims description 71
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 39
229940079593 drug Drugs 0.000 claims description 25
239000003814 drug Substances 0.000 claims description 25
239000000443 aerosol Substances 0.000 claims description 14
206010020751 Hypersensitivity Diseases 0.000 claims description 13
208000026935 allergic disease Diseases 0.000 claims description 13
230000009610 hypersensitivity Effects 0.000 claims description 13
210000002345 respiratory system Anatomy 0.000 claims description 11
239000000843 powder Substances 0.000 claims description 10
230000014508 negative regulation of coagulation Effects 0.000 claims description 7
239000000243 solution Substances 0.000 claims description 7
GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
239000002775 capsule Substances 0.000 claims description 4
150000002016 disaccharides Chemical class 0.000 claims description 4
239000003380 propellant Substances 0.000 claims description 4
150000004044 tetrasaccharides Chemical class 0.000 claims description 4
230000001225 therapeutic effect Effects 0.000 claims description 4
150000004043 trisaccharides Chemical class 0.000 claims description 4
230000003385 bacteriostatic effect Effects 0.000 claims description 3
239000000644 isotonic solution Substances 0.000 claims description 3
239000008101 lactose Substances 0.000 claims description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
239000006199 nebulizer Substances 0.000 claims description 2
238000005086 pumping Methods 0.000 claims 2
239000008365 aqueous carrier Substances 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
230000001684 chronic effect Effects 0.000 abstract description 4
208000002200 Respiratory Hypersensitivity Diseases 0.000 abstract description 2
230000010085 airway hyperresponsiveness Effects 0.000 abstract 1
229940087051 fragmin Drugs 0.000 description 27
230000000694 effects Effects 0.000 description 25
206010006487 Bronchostenosis Diseases 0.000 description 16
230000000172 allergic effect Effects 0.000 description 13
208000010668 atopic eczema Diseases 0.000 description 13
241001494479 Pecora Species 0.000 description 10
AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 10
229960004484 carbachol Drugs 0.000 description 10
238000002474 experimental method Methods 0.000 description 9
230000005713 exacerbation Effects 0.000 description 8
206010066091 Bronchial Hyperreactivity Diseases 0.000 description 7
230000036427 bronchial hyperreactivity Effects 0.000 description 7
239000003055 low molecular weight heparin Substances 0.000 description 7
208000009079 Bronchial Spasm Diseases 0.000 description 6
208000014181 Bronchial disease Diseases 0.000 description 6
206010006482 Bronchospasm Diseases 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
239000002565 heparin fraction Substances 0.000 description 6
230000002685 pulmonary effect Effects 0.000 description 6
230000009257 reactivity Effects 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 5
210000003630 histaminocyte Anatomy 0.000 description 5
210000004072 lung Anatomy 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
230000035945 sensitivity Effects 0.000 description 5
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
208000023819 chronic asthma Diseases 0.000 description 4
239000003246 corticosteroid Substances 0.000 description 4
229960001334 corticosteroids Drugs 0.000 description 4
239000007788 liquid Substances 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
238000010171 animal model Methods 0.000 description 3
239000003146 anticoagulant agent Substances 0.000 description 3
229940127219 anticoagulant drug Drugs 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
239000004019 antithrombin Substances 0.000 description 3
230000008859 change Effects 0.000 description 3
230000001186 cumulative effect Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000002858 neurotransmitter agent Substances 0.000 description 3
230000002265 prevention Effects 0.000 description 3
230000029058 respiratory gaseous exchange Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
108010094028 Prothrombin Proteins 0.000 description 2
208000037656 Respiratory Sounds Diseases 0.000 description 2
108090000190 Thrombin Proteins 0.000 description 2
206010047924 Wheezing Diseases 0.000 description 2
239000000808 adrenergic beta-agonist Substances 0.000 description 2
208000037883 airway inflammation Diseases 0.000 description 2
239000013566 allergen Substances 0.000 description 2
201000009961 allergic asthma Diseases 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000012634 fragment Substances 0.000 description 2
150000004676 glycans Polymers 0.000 description 2
229960001340 histamine Drugs 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
150000004804 polysaccharides Polymers 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 2
239000002904 solvent Substances 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
210000000115 thoracic cavity Anatomy 0.000 description 2
229960004072 thrombin Drugs 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000032258 transport Effects 0.000 description 2
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical group O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
206010027654 Allergic conditions Diseases 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
206010003557 Asthma exercise induced Diseases 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
206010008469 Chest discomfort Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
101100284769 Drosophila melanogaster hemo gene Proteins 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
241000244206 Nematoda Species 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
230000002429 anti-coagulating effect Effects 0.000 description 1
230000007503 antigenic stimulation Effects 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
229940125388 beta agonist Drugs 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
229940019700 blood coagulation factors Drugs 0.000 description 1
230000037182 bone density Effects 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
230000001813 broncholytic effect Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
229960000265 cromoglicic acid Drugs 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
229940124447 delivery agent Drugs 0.000 description 1
238000011161 development Methods 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
230000003090 exacerbative effect Effects 0.000 description 1
208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
239000003966 growth inhibitor Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
229940125369 inhaled corticosteroids Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000004199 lung function Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
238000002663 nebulization Methods 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
230000001734 parasympathetic effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000008196 pharmacological composition Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229940043274 prophylactic drug Drugs 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
230000011514 reflex Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000028327 secretion Effects 0.000 description 1
208000013220 shortness of breath Diseases 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
241000894007 species Species 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Dispersion Chemistry (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

UA98020876A 1995-08-18 1996-08-13 Method (variants) and composition for treating asthma UA62919C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/516,786 US5690910A (en)	1995-08-18	1995-08-18	Method for treating asthma
PCT/US1996/013133 WO1997006783A1 (en)	1995-08-18	1996-08-13	Method and composition for treating asthma

Publications (1)

Publication Number	Publication Date
UA62919C2 true UA62919C2 (en)	2004-01-15

Family

ID=24057086

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA98020876A UA62919C2 (en)	1995-08-18	1996-08-13	Method (variants) and composition for treating asthma

Country Status (21)

Country	Link
US (1)	US5690910A (da)
EP (1)	EP0844869B1 (da)
JP (1)	JP3263723B2 (da)
KR (1)	KR100451901B1 (da)
AR (1)	AR003271A1 (da)
AT (1)	ATE300938T1 (da)
AU (1)	AU701691B2 (da)
CA (1)	CA2229060A1 (da)
CZ (1)	CZ292134B6 (da)
DE (1)	DE69635023T2 (da)
DK (1)	DK0844869T3 (da)
ES (1)	ES2244974T3 (da)
HU (1)	HUP9901614A3 (da)
IL (1)	IL123166A (da)
NZ (2)	NZ315275A (da)
PL (1)	PL186912B1 (da)
PT (1)	PT844869E (da)
SK (1)	SK282759B6 (da)
UA (1)	UA62919C2 (da)
WO (1)	WO1997006783A1 (da)
ZA (1)	ZA966838B (da)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2528093C2 (ru) *	2010-07-21	2014-09-10	Олег Ильич Эпштейн	Фармацевтическая композиция и способ лечения острых и хронических заболевания дыхательной системы и синдрома кашля

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5980865A (en) *	1995-08-18	1999-11-09	Baker Norton Pharmaceuticals, Inc.	Method for treating late phase allergic reactions and inflammatory diseases
US7056504B1 (en)	1998-08-27	2006-06-06	Massachusetts Institute Of Technology	Rationally designed heparinases derived from heparinase I and II
EP1109919A2 (en)	1998-08-27	2001-06-27	Massachusetts Institute Of Technology	Rationally designed heparinases derived from heparinase i and ii
US6235725B1 (en) *	1998-10-30	2001-05-22	Baker Norton Pharmaceuticals, Inc.	Methods and compositions for the prevention of tolerance to medications
SI1124563T1 (en) *	1998-10-30	2005-02-28	Ivax Research, Inc.	Methods and compositions for the prevention of tolerance to bronchodilators
US7412332B1 (en)	1999-04-23	2008-08-12	Massachusetts Institute Of Technology	Method for analyzing polysaccharides
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
WO2001066772A2 (en)	2000-03-08	2001-09-13	Massachusetts Institute Of Technology	Heparinase iii and uses thereof
AU2001264817A1 (en) *	2000-05-23	2001-12-17	Exhale Therapeutics, Inc.	Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans
ATE426805T1 (de)	2000-09-12	2009-04-15	Massachusetts Inst Technology	Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind
AU2440802A (en) *	2000-10-18	2002-04-29	Massachusetts Inst Technology	Methods and products related to pulmonary delivery of polysaccharides
WO2003080149A2 (en)	2002-03-20	2003-10-02	Mannkind Corporation	Inhalation apparatus
US20040171819A1 (en)	2002-10-10	2004-09-02	Aventis Pharma S.A.	Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
US20040152694A1 (en) *	2003-02-04	2004-08-05	Istvan Kurucz	Methods and compositions for treating inflammatory disorders of the airways
GB0327723D0 (en) *	2003-09-15	2003-12-31	Vectura Ltd	Pharmaceutical compositions
PL1786784T3 (pl)	2004-08-20	2011-04-29	Mannkind Corp	Kataliza syntezy diketopiperazyn
KR101644250B1 (ko)	2004-08-23	2016-07-29	맨카인드 코포레이션	약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
EP1791555B1 (en) *	2004-09-10	2013-03-13	Pharmaorigin ApS	Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis
CN104324362B (zh)	2005-09-14	2018-04-24	曼金德公司	以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
IN2015DN00888A (da)	2006-02-22	2015-07-10	Mannkind Corp
US8592393B2 (en)	2007-11-02	2013-11-26	Momenta Pharmaceuticals, Inc.	Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8569262B2 (en)	2007-11-02	2013-10-29	Momenta Pharmaceuticals, Inc.	Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
ES2567079T3 (es) *	2007-11-02	2016-04-19	Momenta Pharmaceuticals, Inc.	Composiciones de polisacáridos que no son anticoagulantes
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
ES2929343T3 (es)	2008-06-13	2022-11-28	Mannkind Corp	Inhalador de polvo seco accionado por aspiración para la administración de fármacos
KR101628410B1 (ko)	2008-06-20	2016-06-08	맨카인드 코포레이션	흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
TWI614024B (zh)	2008-08-11	2018-02-11	曼凱公司	超快起作用胰島素之用途
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
DK2405963T3 (da)	2009-03-11	2013-12-16	Mannkind Corp	Apparat, system og fremgangsmåde til at måle modstand i en inhalator
CN104721825B (zh)	2009-06-12	2019-04-12	曼金德公司	具有确定比表面积的二酮哌嗪颗粒
WO2011056889A1 (en)	2009-11-03	2011-05-12	Mannkind Corporation	An apparatus and method for simulating inhalation efforts
RU2576033C2 (ru) *	2009-12-03	2016-02-27	Опко Хелс, Инк.	Составы на основе гиперсулфатированных дисахаридов
US9387256B2 (en)	2010-04-16	2016-07-12	Momenta Pharmaceuticals, Inc.	Tissue targeting
WO2011159770A2 (en)	2010-06-17	2011-12-22	Momenta Pharmaceuticals, Inc.	Methods and compositions for modulating hair growth
IL223742A (en)	2010-06-21	2016-06-30	Mannkind Corp	A dry powder inhaler and preparation for it
US20130203695A1 (en) *	2010-10-29	2013-08-08	Opko Health, Inc.	Hypersulfated disaccharides to treat elastase related disorders
AU2012236150B2 (en)	2011-04-01	2016-03-31	Mannkind Corporation	Blister package for pharmaceutical cartridges
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
BR112014009686A2 (pt)	2011-10-24	2018-08-07	Mannkind Corp	composição analgésica inalável, pó seco e método para tratar dor
CN104619369B (zh)	2012-07-12	2018-01-30	曼金德公司	干粉药物输送系统和方法
US10159644B2 (en)	2012-10-26	2018-12-25	Mannkind Corporation	Inhalable vaccine compositions and methods
AU2014228415B2 (en)	2013-03-15	2018-08-09	Mannkind Corporation	Microcrystalline diketopiperazine compositions and methods
US10016449B2 (en)	2013-05-28	2018-07-10	Momenta Pharmaceuticals, Inc.	Pharmaceutical compositions
MX375448B (es)	2013-07-18	2025-03-06	Mannkind Corp	Composiciones farmacéuticas en polvo seco estables al calor y métodos.
US11446127B2 (en)	2013-08-05	2022-09-20	Mannkind Corporation	Insufflation apparatus and methods
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
EP3500583A1 (en)	2016-08-16	2019-06-26	OPKO Pharmaceuticals, LLC	Pure heptasulfated disaccharides having improved oral bioavailability

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2111002C (en) *	1991-06-10	2000-08-22	Julianne Fassberg	Non-chlorofluorocarbon aerosol formulations
WO1993019734A1 (en) *	1992-04-02	1993-10-14	Baker Norton Pharmaceuticals, Inc.	Method and composition for treating antigen-induced and exercise-induced asthma

1995
- 1995-08-18 US US08/516,786 patent/US5690910A/en not_active Expired - Fee Related
1996
- 1996-08-13 NZ NZ315275A patent/NZ315275A/xx not_active IP Right Cessation
- 1996-08-13 DK DK96926952T patent/DK0844869T3/da active
- 1996-08-13 CA CA002229060A patent/CA2229060A1/en not_active Abandoned
- 1996-08-13 PL PL96324970A patent/PL186912B1/pl unknown
- 1996-08-13 AU AU66945/96A patent/AU701691B2/en not_active Expired
- 1996-08-13 KR KR10-1998-0701167A patent/KR100451901B1/ko not_active Expired - Lifetime
- 1996-08-13 ES ES96926952T patent/ES2244974T3/es not_active Expired - Lifetime
- 1996-08-13 IL IL12316696A patent/IL123166A/en not_active IP Right Cessation
- 1996-08-13 DE DE69635023T patent/DE69635023T2/de not_active Expired - Lifetime
- 1996-08-13 JP JP50942897A patent/JP3263723B2/ja not_active Expired - Lifetime
- 1996-08-13 AT AT96926952T patent/ATE300938T1/de active
- 1996-08-13 HU HU9901614A patent/HUP9901614A3/hu unknown
- 1996-08-13 EP EP96926952A patent/EP0844869B1/en not_active Expired - Lifetime
- 1996-08-13 WO PCT/US1996/013133 patent/WO1997006783A1/en not_active Ceased
- 1996-08-13 SK SK172-98A patent/SK282759B6/sk not_active IP Right Cessation
- 1996-08-13 PT PT96926952T patent/PT844869E/pt unknown
- 1996-08-13 ZA ZA9606838A patent/ZA966838B/xx unknown
- 1996-08-13 CZ CZ1998481A patent/CZ292134B6/cs not_active IP Right Cessation
- 1996-08-13 UA UA98020876A patent/UA62919C2/uk unknown
- 1996-08-15 AR ARP960103997A patent/AR003271A1/es not_active Application Discontinuation
1999
- 1999-09-23 NZ NZ337996A patent/NZ337996A/en not_active IP Right Cessation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2528093C2 (ru) *	2010-07-21	2014-09-10	Олег Ильич Эпштейн	Фармацевтическая композиция и способ лечения острых и хронических заболевания дыхательной системы и синдрома кашля

Also Published As

Publication number	Publication date
CZ48198A3 (cs)	1998-11-11
HUP9901614A3 (en)	2000-04-28
EP0844869A4 (en)	2003-04-09
SK282759B6 (sk)	2002-12-03
AU6694596A (en)	1997-03-12
CZ292134B6 (cs)	2003-08-13
US5690910A (en)	1997-11-25
PL324970A1 (en)	1998-06-22
AU701691B2 (en)	1999-02-04
SK17298A3 (en)	1998-09-09
NZ315275A (en)	2000-01-28
EP0844869B1 (en)	2005-08-03
ATE300938T1 (de)	2005-08-15
EP0844869A1 (en)	1998-06-03
DK0844869T3 (da)	2005-12-12
KR19990037688A (ko)	1999-05-25
HUP9901614A2 (hu)	1999-09-28
JPH11511196A (ja)	1999-09-28
AR003271A1 (es)	1998-07-08
HK1007060A1 (en)	1999-04-01
JP3263723B2 (ja)	2002-03-11
DE69635023T2 (de)	2006-05-24
NZ337996A (en)	2001-04-27
IL123166A (en)	2002-07-25
KR100451901B1 (ko)	2005-09-12
WO1997006783A1 (en)	1997-02-27
IL123166A0 (en)	1998-09-24
MX9801165A (es)	1998-07-31
CA2229060A1 (en)	1997-02-27
ZA966838B (en)	1997-02-19
PL186912B1 (pl)	2004-03-31
PT844869E (pt)	2005-10-31
DE69635023D1 (de)	2005-09-08
ES2244974T3 (es)	2005-12-16

Publication	Publication Date	Title
UA62919C2 (en)	2004-01-15	Method (variants) and composition for treating asthma
KR100551773B1 (ko)	2006-02-13	후기 알러지 반응 및 염증 질환 치료방법 및 조성물
CA2359813C (en)	2008-04-22	Nicotine mucosal spray
US5783188A (en)	1998-07-21	Method of treating rheumatoid arthritis with type collagen peptide fragments containing repeating sequences
AU2018253538B2 (en)	2020-08-20	Levodopa formulations for rapid relief of parkinson's disease
WO2022009081A1 (en)	2022-01-13	Drug for use against the novel coronavirus disease, covid-19
WO1993019734A1 (en)	1993-10-14	Method and composition for treating antigen-induced and exercise-induced asthma
Bleecker et al.	1991	Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease
RU2179445C2 (ru)	2002-02-20	Способ и композиция для лечения астмы
KR20150101993A (ko)	2015-09-04	레보도파 혈장 농도의 환자간 변산도의 감소
MXPA98001165A (en)	1998-11-09	Method and composition for the treatment of the
HK1007060B (en)	2005-10-28	Ulmwh (ultra-low-molecular weight heparin) for treating asthma
AU775161B2 (en)	2004-07-22	Method and compositions for treating late phase allergic reactions and inflammatory diseases
MXPA00000992A (en)	2001-05-07	Method and compositions for treating late phase allergic reactions and inflammatory diseases
MXPA00009704A (en)	2001-07-09	Pulmonary and nasal delivery of raloxifene

UA62919C2 - Method (variants) and composition for treating asthma - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=24057086

Family Applications (1)

Country Status (21)

Cited By (1)

Families Citing this family (48)

Family Cites Families (2)

Cited By (1)

Also Published As

Similar Documents